REGENERON PHARMACEUTICALS (RGO.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:RGO • US75886F1075

639.6 EUR
+20.8 (+3.36%)
Last: Feb 2, 2026, 07:00 PM
Fundamental Rating

6

Overall RGO gets a fundamental rating of 6 out of 10. We evaluated RGO against 84 industry peers in the Biotechnology industry. RGO gets an excellent profitability rating and is at the same time showing great financial health properties. RGO has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • RGO had positive earnings in the past year.
  • In the past year RGO had a positive cash flow from operations.
  • Of the past 5 years RGO 4 years were profitable.
  • RGO had a positive operating cash flow in 4 of the past 5 years.
RGO.DE Yearly Net Income VS EBIT VS OCF VS FCFRGO.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 11.40%, RGO belongs to the top of the industry, outperforming 86.90% of the companies in the same industry.
  • RGO has a Return On Equity of 14.79%. This is amongst the best in the industry. RGO outperforms 85.71% of its industry peers.
  • With an excellent Return On Invested Capital value of 7.75%, RGO belongs to the best of the industry, outperforming 85.71% of the companies in the same industry.
  • RGO had an Average Return On Invested Capital over the past 3 years of 11.09%. This is in line with the industry average of 11.98%.
Industry RankSector Rank
ROA 11.4%
ROE 14.79%
ROIC 7.75%
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)11.09%
ROIC(5y)16.16%
RGO.DE Yearly ROA, ROE, ROICRGO.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

  • The Profit Margin of RGO (32.13%) is better than 89.29% of its industry peers.
  • RGO's Profit Margin has improved in the last couple of years.
  • RGO has a better Operating Margin (27.61%) than 84.52% of its industry peers.
  • In the last couple of years the Operating Margin of RGO has declined.
  • RGO has a Gross Margin of 86.28%. This is amongst the best in the industry. RGO outperforms 80.95% of its industry peers.
  • In the last couple of years the Gross Margin of RGO has remained more or less at the same level.
Industry RankSector Rank
OM 27.61%
PM (TTM) 32.13%
GM 86.28%
OM growth 3Y-19.71%
OM growth 5Y-2.68%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.28%
GM growth 5Y-0.68%
RGO.DE Yearly Profit, Operating, Gross MarginsRGO.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

8

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), RGO is creating some value.
  • There is no outstanding debt for RGO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RGO.DE Yearly Shares OutstandingRGO.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
RGO.DE Yearly Total Debt VS Total AssetsRGO.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

2.2 Solvency

  • RGO has an Altman-Z score of 7.49. This indicates that RGO is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 7.49, RGO belongs to the best of the industry, outperforming 84.52% of the companies in the same industry.
  • The Debt to FCF ratio of RGO is 0.70, which is an excellent value as it means it would take RGO, only 0.70 years of fcf income to pay off all of its debts.
  • RGO has a Debt to FCF ratio of 0.70. This is amongst the best in the industry. RGO outperforms 88.10% of its industry peers.
  • A Debt/Equity ratio of 0.09 indicates that RGO is not too dependend on debt financing.
  • RGO has a better Debt to Equity ratio (0.09) than 65.48% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 0.7
Altman-Z 7.49
ROIC/WACC0.9
WACC8.61%
RGO.DE Yearly LT Debt VS Equity VS FCFRGO.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.3 Liquidity

  • A Current Ratio of 4.06 indicates that RGO has no problem at all paying its short term obligations.
  • RGO has a Current ratio of 4.06. This is in the better half of the industry: RGO outperforms 77.38% of its industry peers.
  • RGO has a Quick Ratio of 3.51. This indicates that RGO is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of RGO (3.51) is better than 71.43% of its industry peers.
Industry RankSector Rank
Current Ratio 4.06
Quick Ratio 3.51
RGO.DE Yearly Current Assets VS Current LiabilitesRGO.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

More info and screens

3

3. Growth

3.1 Past

  • RGO shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.76%.
  • Measured over the past 5 years, RGO shows a small growth in Earnings Per Share. The EPS has been growing by 6.99% on average per year.
EPS 1Y (TTM)-2.76%
EPS 3Y1.53%
EPS 5Y6.99%
EPS Q2Q%-5.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%2.51%

3.2 Future

  • RGO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.05% yearly.
  • The Revenue is expected to grow by 7.12% on average over the next years.
EPS Next Y4.14%
EPS Next 2Y12.18%
EPS Next 3Y8.22%
EPS Next 5Y10.05%
Revenue Next Year6.89%
Revenue Next 2Y8.55%
Revenue Next 3Y7.27%
Revenue Next 5Y7.12%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
RGO.DE Yearly Revenue VS EstimatesRGO.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B 20B
RGO.DE Yearly EPS VS EstimatesRGO.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20 40 60

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

  • RGO is valuated rather expensively with a Price/Earnings ratio of 17.07.
  • 90.48% of the companies in the same industry are more expensive than RGO, based on the Price/Earnings ratio.
  • RGO is valuated rather cheaply when we compare the Price/Earnings ratio to 28.41, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 16.39, RGO is valued correctly.
  • RGO's Price/Forward Earnings ratio is rather cheap when compared to the industry. RGO is cheaper than 85.71% of the companies in the same industry.
  • RGO is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 25.64, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 17.07
Fwd PE 16.39
RGO.DE Price Earnings VS Forward Price EarningsRGO.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of RGO indicates a somewhat cheap valuation: RGO is cheaper than 79.76% of the companies listed in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of RGO indicates a rather cheap valuation: RGO is cheaper than 84.52% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 20.51
EV/EBITDA 15.23
RGO.DE Per share dataRGO.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 50 100 150 200

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates RGO does not grow enough to justify the current Price/Earnings ratio.
  • The decent profitability rating of RGO may justify a higher PE ratio.
PEG (NY)4.12
PEG (5Y)2.44
EPS Next 2Y12.18%
EPS Next 3Y8.22%

More info and screens

2

5. Dividend

5.1 Amount

  • RGO has a yearly dividend return of 0.47%, which is pretty low.
  • Compared to an average industry Dividend Yield of 0.66, RGO pays a better dividend. On top of this RGO pays more dividend than 90.48% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.83, RGO's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.47%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
RGO.DE Yearly Dividends per shareRGO.DE Yearly Dividends per shareYearly Dividends per share 2025 2026 0.2 0.4 0.6 0.8

5.3 Sustainability

DPN/A
EPS Next 2Y12.18%
EPS Next 3Y8.22%
RGO.DE Yearly Income VS Free CF VS DividendRGO.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

More info and screens

REGENERON PHARMACEUTICALS

FRA:RGO (2/2/2026, 7:00:00 PM)

639.6

+20.8 (+3.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-30
Earnings (Next)04-27
Inst Owners90.13%
Inst Owner ChangeN/A
Ins Owners1.95%
Ins Owner ChangeN/A
Market Cap67.22B
Revenue(TTM)N/A
Net Income(TTM)4.58B
Analysts79.44
Price Target733.93 (14.75%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.47%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)35.37%
Min EPS beat(2)20.96%
Max EPS beat(2)49.77%
EPS beat(4)3
Avg EPS beat(4)16.75%
Min EPS beat(4)-8.66%
Max EPS beat(4)49.77%
EPS beat(8)6
Avg EPS beat(8)9.92%
EPS beat(12)10
Avg EPS beat(12)9.47%
EPS beat(16)13
Avg EPS beat(16)8.82%
Revenue beat(2)2
Avg Revenue beat(2)6.19%
Min Revenue beat(2)2.66%
Max Revenue beat(2)9.72%
Revenue beat(4)2
Avg Revenue beat(4)0.54%
Min Revenue beat(4)-9.32%
Max Revenue beat(4)9.72%
Revenue beat(8)4
Avg Revenue beat(8)0.34%
Revenue beat(12)8
Avg Revenue beat(12)1.48%
Revenue beat(16)12
Avg Revenue beat(16)2.04%
PT rev (1m)6.87%
PT rev (3m)-16.26%
EPS NQ rev (1m)0.35%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.61%
EPS NY rev (3m)-7.56%
Revenue NQ rev (1m)0.65%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.11%
Revenue NY rev (3m)0.76%
Valuation
Industry RankSector Rank
PE 17.07
Fwd PE 16.39
P/S 5.59
P/FCF 20.51
P/OCF 15.7
P/B 2.57
P/tB 2.69
EV/EBITDA 15.23
EPS(TTM)37.48
EY5.86%
EPS(NY)39.03
Fwd EY6.1%
FCF(TTM)31.19
FCFY4.88%
OCF(TTM)40.75
OCFY6.37%
SpS114.5
BVpS248.78
TBVpS237.68
PEG (NY)4.12
PEG (5Y)2.44
Graham Number458.04
Profitability
Industry RankSector Rank
ROA 11.4%
ROE 14.79%
ROCE 11.01%
ROIC 7.75%
ROICexc 10.14%
ROICexgc 10.68%
OM 27.61%
PM (TTM) 32.13%
GM 86.28%
FCFM 27.24%
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)11.09%
ROIC(5y)16.16%
ROICexc(3y)16.12%
ROICexc(5y)22.5%
ROICexgc(3y)16.99%
ROICexgc(5y)23.02%
ROCE(3y)15.75%
ROCE(5y)22.96%
ROICexgc growth 3Y-32.64%
ROICexgc growth 5Y-8.74%
ROICexc growth 3Y-33.7%
ROICexc growth 5Y-9.6%
OM growth 3Y-19.71%
OM growth 5Y-2.68%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.28%
GM growth 5Y-0.68%
F-Score5
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 0.7
Debt/EBITDA 0.61
Cap/Depr 226.62%
Cap/Sales 8.35%
Interest Coverage 250
Cash Conversion 113.73%
Profit Quality 84.78%
Current Ratio 4.06
Quick Ratio 3.51
Altman-Z 7.49
F-Score5
WACC8.61%
ROIC/WACC0.9
Cap/Depr(3y)292.07%
Cap/Depr(5y)265.92%
Cap/Sales(3y)8.85%
Cap/Sales(5y)7.44%
Profit Quality(3y)83.76%
Profit Quality(5y)77.83%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.76%
EPS 3Y1.53%
EPS 5Y6.99%
EPS Q2Q%-5.22%
EPS Next Y4.14%
EPS Next 2Y12.18%
EPS Next 3Y8.22%
EPS Next 5Y10.05%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%2.51%
Revenue Next Year6.89%
Revenue Next 2Y8.55%
Revenue Next 3Y7.27%
Revenue Next 5Y7.12%
EBIT growth 1Y-6.18%
EBIT growth 3Y-22.95%
EBIT growth 5Y9.54%
EBIT Next Year-5.06%
EBIT Next 3Y6.25%
EBIT Next 5Y11.85%
FCF growth 1Y-10.97%
FCF growth 3Y-18.47%
FCF growth 5Y12.09%
OCF growth 1Y-2.93%
OCF growth 3Y-14.54%
OCF growth 5Y12.71%

REGENERON PHARMACEUTICALS / RGO.DE FAQ

Can you provide the ChartMill fundamental rating for REGENERON PHARMACEUTICALS?

ChartMill assigns a fundamental rating of 6 / 10 to RGO.DE.


Can you provide the valuation status for REGENERON PHARMACEUTICALS?

ChartMill assigns a valuation rating of 6 / 10 to REGENERON PHARMACEUTICALS (RGO.DE). This can be considered as Fairly Valued.


Can you provide the profitability details for REGENERON PHARMACEUTICALS?

REGENERON PHARMACEUTICALS (RGO.DE) has a profitability rating of 7 / 10.


What are the PE and PB ratios of REGENERON PHARMACEUTICALS (RGO.DE) stock?

The Price/Earnings (PE) ratio for REGENERON PHARMACEUTICALS (RGO.DE) is 17.07 and the Price/Book (PB) ratio is 2.57.